Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis

Next Previous
Trial Profile

A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nesolicaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Proteostasis Therapeutics

Most Recent Events

  • 23 May 2018 Results assessing the relationship between nasal CFTR protein levels with lung function changes in response to lumacaftor-ivacaftor treatment for Phe508del homozygous CF patients, presented at the 114th International Conference of the American Thoracic Society
  • 20 Mar 2018 According to a Proteostasis Therapeutics media release, based on the data from this trial, triple combination study (see profile 292094 ) protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018.
  • 14 Mar 2018 Results published in the Proteostasis Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top